297 related articles for article (PubMed ID: 25691036)
21. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia.
Taher AT; Porter JB; Viprakasit V; Kattamis A; Chuncharunee S; Sutcharitchan P; Siritanaratkul N; Origa R; Karakas Z; Habr D; Zhu Z; Cappellini MD
Br J Haematol; 2015 Jan; 168(2):284-90. PubMed ID: 25212456
[TBL] [Abstract][Full Text] [Related]
22. Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients.
Pakbaz Z; Fischer R; Fung E; Nielsen P; Harmatz P; Vichinsky E
Pediatr Blood Cancer; 2007 Sep; 49(3):329-32. PubMed ID: 17554789
[TBL] [Abstract][Full Text] [Related]
23. Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome.
Escudero-Vilaplana V; Garcia-Gonzalez X; Osorio-Prendes S; Romero-Jimenez RM; Sanjurjo-Saez M
J Clin Pharm Ther; 2016 Feb; 41(1):59-63. PubMed ID: 26778738
[TBL] [Abstract][Full Text] [Related]
24. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD
Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
[TBL] [Abstract][Full Text] [Related]
25. [Study of iron overload assessment by T2* magnetic resonance imaging in patients with myelodysplastic syndromes].
Song LL; Lu HY; Xiao C; Wu LY; Wu D; Su JY; Zhou LY; Chang CK
Zhonghua Xue Ye Xue Za Zhi; 2019 Mar; 40(3):222-226. PubMed ID: 30929390
[No Abstract] [Full Text] [Related]
26. Efficacy of Deferasirox for the treatment of iron overload in Chinese thalassaemia major patients: results from a prospective, open-label, multicentre clinical trial.
Lai YR; Liu RR; Li CF; Huang SL; Li Q; Habr D; Martin N; Shen ZX
Transfus Med; 2013 Dec; 23(6):389-96. PubMed ID: 24147622
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
Karimi M; Arandi N; Haghpanah S; Ansari S; Azarkeyvan A; Bordbar M; Safaei S
Hemoglobin; 2015; 39(5):327-9. PubMed ID: 26114738
[TBL] [Abstract][Full Text] [Related]
28. Assessment of liver and cardiac iron overload using MRI in patients with chronic anemias in Latin American countries: results from ASIMILA study.
Cancado R; Watman NP; Lobo C; Chona Z; Manzur F; Traina F; Park M; Drelichman G; Zarate JP; Marfil L
Hematology; 2018 Oct; 23(9):676-682. PubMed ID: 29663858
[TBL] [Abstract][Full Text] [Related]
29. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome.
List AF; Baer MR; Steensma DP; Raza A; Esposito J; Martinez-Lopez N; Paley C; Feigert J; Besa E
J Clin Oncol; 2012 Jun; 30(17):2134-9. PubMed ID: 22547607
[TBL] [Abstract][Full Text] [Related]
30. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
[TBL] [Abstract][Full Text] [Related]
31. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study.
Porter J; Galanello R; Saglio G; Neufeld EJ; Vichinsky E; Cappellini MD; Olivieri N; Piga A; Cunningham MJ; Soulières D; Gattermann N; Tchernia G; Maertens J; Giardina P; Kwiatkowski J; Quarta G; Jeng M; Forni GL; Stadler M; Cario H; Debusscher L; Della Porta M; Cazzola M; Greenberg P; Alimena G; Rabault B; Gathmann I; Ford JM; Alberti D; Rose C
Eur J Haematol; 2008 Feb; 80(2):168-76. PubMed ID: 18028431
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
[TBL] [Abstract][Full Text] [Related]
33. Iron chelation therapy in MDS: what have we learnt recently?
Schmid M
Blood Rev; 2009 Dec; 23 Suppl 1():S21-5. PubMed ID: 20116636
[TBL] [Abstract][Full Text] [Related]
34. Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload.
Puliyel M; Sposto R; Berdoukas VA; Hofstra TC; Nord A; Carson S; Wood J; Coates TD
Am J Hematol; 2014 Apr; 89(4):391-4. PubMed ID: 24347294
[TBL] [Abstract][Full Text] [Related]
35. Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study.
Taher AT; Porter JB; Viprakasit V; Kattamis A; Chuncharunee S; Sutcharitchan P; Siritanaratkul N; Galanello R; Karakas Z; Lawniczek T; Habr D; Ros J; Zhu Z; Cappellini MD
Ann Hematol; 2013 Nov; 92(11):1485-93. PubMed ID: 23775581
[TBL] [Abstract][Full Text] [Related]
36. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
Piga A; Galanello R; Forni GL; Cappellini MD; Origa R; Zappu A; Donato G; Bordone E; Lavagetto A; Zanaboni L; Sechaud R; Hewson N; Ford JM; Opitz H; Alberti D
Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
[TBL] [Abstract][Full Text] [Related]
37. Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
Maurillo L; Breccia M; Buccisano F; Voso MT; Niscola P; Trapè G; Tatarelli C; D'Addosio A; Latagliata R; Fenu S; Piccioni AL; Fragasso A; Aloe Spiriti MA; Refrigeri M; Criscuolo M; Musto P; Venditti A
Eur J Haematol; 2015 Jul; 95(1):52-6. PubMed ID: 25764148
[TBL] [Abstract][Full Text] [Related]
38. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.
Gattermann N; Finelli C; Porta MD; Fenaux P; Ganser A; Guerci-Bresler A; Schmid M; Taylor K; Vassilieff D; Habr D; Domokos G; Roubert B; Rose C;
Leuk Res; 2010 Sep; 34(9):1143-50. PubMed ID: 20451251
[TBL] [Abstract][Full Text] [Related]
39. Delineating parameters of iron overload in MDS patients treated with deferasirox.
Leitch HA
Leuk Res; 2010 Dec; 34(12):1556-7. PubMed ID: 20719382
[No Abstract] [Full Text] [Related]
40. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]